Form 8-K - Current report:
SEC Accession No. 0000950170-24-105344
Filing Date
2024-09-11
Accepted
2024-09-11 08:35:09
Documents
15
Period of Report
2024-09-11
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ktra-20240911.htm   iXBRL 8-K 72907
2 EX-99.1 ktra-ex99_1.htm EX-99.1 42294
3 EX-99.2 ktra-ex99_2.htm EX-99.2 23773
4 GRAPHIC img40499469_0.jpg GRAPHIC 115627
5 GRAPHIC img41422990_0.jpg GRAPHIC 24913
  Complete submission text file 0000950170-24-105344.txt   476078

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ktra-20240911.xsd EX-101.SCH 27216
17 EXTRACTED XBRL INSTANCE DOCUMENT ktra-20240911_htm.xml XML 4909
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 150 SAN DIEGO CA 92121 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

EIN.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-37823 | Film No.: 241291479
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)